Kinnate Biopharma Investor Presentation — March 2022

Document content

Investor Presentation

March 2022Thispresentation (including theaccompanying oral presentation) contains forward -looking statements that involve substantial risks and uncertainties .Allstatements other than statements ofhistorical

facts contained inthispresentation, including statements regarding thefuture financial condition, results ofoperations, business strategy and plans, and objectives ofmanagement forfuture operations

ofKinnate Biopharma Inc.("we," "us"or"our") ,aswell asstatements regarding industry trends, areforward -looking statements .Insome cases, you can identify forward -looking statements byterminology

such as“anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially” “predict,” “should,” “will” orthenegative ofthese terms orother similar expressions .We

have based these forward -looking statements largely onourcurrent expectations and projections about future events and trends that webelieve may affect ourfinancial condition, results of

operations, business strategy and financial needs .

These forward -looking statements aresubject toanumber ofrisks, uncertainties and assumptions, including, among other things :ourability tosuccessfully complete ourongoing clinical trialand forthat

trial toproduce positive results, thetiming oftheinitiation, progress and potential results ofourongoing and planned preclinical studies and clinical trials and ourresearch programs ;ourability to

advance additional product candidates into, and successfully complete, preclinical studies and clinical trials with those additional product candidates ;thetiming orlikelihood ofregulatory filings and

approvals ;thenegative impacts oftheCOVID -19pandemic ;ourestimates ofthenumber ofpatients who suffer from thediseases wearetargeting and thenumber ofpatients that may enroll inour

clinical trials ;thecommercializing ofourproduct candidates, ifapproved ;ourability and thepotential tosuccessfully manufacture and supply ourproduct candidates forclinical trials and for

commercial use, ifapproved ;future strategic arrangements and/or collaborations and the potential benefits ofsuch arrangements; our estimates regarding expenses, future revenue, capital

requirements and needs forfinancing and ourability toobtain capital ;thesufficiency ofourexisting cash and cash equivalents tofund ourfuture operating expenses and capital expenditure

requirements ;ourability toretain thecontinued service ofourkeypersonnel and toidentify, hire and retain additional qualified professionals ;theimplementation ofourbusiness model, strategic plans

forourbusiness and product candidates ;thescope ofprotection weareable toestablish and maintain forintellectual property rights, product candidates and ourpipeline; ourability tocontract with